IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.5% - Should You Sell?

IDEAYA Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • IDEAYA shares fell 6.5% to $28.39 in mid-day trading, while trading volume was 94% below its average.
  • The FDA aligned with IDEAYA on potential registration plans for IDE849 in neuroendocrine cancers, including a trial that could support accelerated approval; the company aims to begin trials by the end of 2026.
  • Analysts have a “Moderate Buy” consensus and an average $49.55 price target. In its latest quarter, IDEAYA’s loss per share was slightly wider than expected, though revenue rose 14.6% year over year.
  • Five stocks to consider instead of IDEAYA Biosciences.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) fell 6.5% during mid-day trading on Tuesday. The stock traded as low as $28.93 and last traded at $28.3850. Approximately 59,087 shares were traded during trading, a decline of 94% from the average session volume of 1,024,211 shares. The stock had previously closed at $30.36.

Key Stories Impacting IDEAYA Biosciences

These are some of the IDYA stories that stood out recently:

  • Positive Sentiment: The FDA aligned with IDEAYA on potential registration strategies for IDE849 in previously treated neuroendocrine carcinomas. The plans include a single-arm cohort that could support accelerated approval and a randomized Phase 3 trial to support full approval. IDEAYA aims to start the trials by the end of 2026. IDE849 FDA meeting announcement
  • Positive Sentiment: Royal Bank of Canada reaffirmed its “outperform” rating and set a $45 price target, signaling analyst confidence in IDEAYA’s outlook. RBC rating
  • Positive Sentiment: IDEAYA nominated IDE101 as a development candidate, a potential first-in-class treatment targeting CDKN2A-deficient solid tumors. Preclinical activity was reported, and the company is conducting studies intended to support an IND filing in the first half of 2027—an earlier-stage, longer-term pipeline opportunity. IDE101 announcement

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 22nd. Citigroup increased their price objective on shares of IDEAYA Biosciences from $65.00 to $66.00 and gave the stock a "buy" rating in a research report on Thursday, November 5th. Mizuho reduced their target price on IDEAYA Biosciences from $44.00 to $39.00 and set an "outperform" rating for the company in a research note on Monday, November 9th. Truist Financial reaffirmed a "buy" rating and issued a $57.00 target price (down from $59.00) on shares of IDEAYA Biosciences in a research report on Tuesday, November 3rd. Finally, William Blair began coverage on IDEAYA Biosciences in a research note on Friday, October 16th. They set an "outperform" rating on the stock. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $49.55.

Check Out Our Latest Analysis on IDEAYA Biosciences

IDEAYA Biosciences Trading Down 8.5%

The firm has a market cap of $2.69 billion, a P/E ratio of -6.11 and a beta of 0.08. The company's 50-day moving average is $35.28 and its two-hundred day moving average is $33.88.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.18) by ($0.04). IDEAYA Biosciences had a negative return on equity of 39.78% and a negative net margin of 1,157.18%. The company had revenue of $10.24 million for the quarter, compared to the consensus estimate of $7.58 million. During the same period in the prior year, the firm posted $1.33 earnings per share. The business's revenue for the quarter was up 14.6% on a year-over-year basis. Research analysts anticipate that IDEAYA Biosciences, Inc. will post -4.63 EPS for the current fiscal year.

Insider Transactions at IDEAYA Biosciences

In related news, CEO Yujiro Hata sold 26,338 shares of the stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total value of $985,304.58. Following the completion of the sale, the chief executive officer directly owned 690,695 shares of the company's stock, valued at approximately $25,838,899.95. This represents a 3.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 4.70% of the company's stock.

Institutional Trading of IDEAYA Biosciences

Several institutional investors have recently made changes to their positions in the company. Aquatic Capital Management LLC lifted its position in shares of IDEAYA Biosciences by 3,154.0% during the third quarter. Aquatic Capital Management LLC now owns 45,361 shares of the company's stock valued at $1,743,000 after purchasing an additional 43,967 shares in the last quarter. Goldman Sachs Group Inc. grew its position in IDEAYA Biosciences by 18.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,453,997 shares of the company's stock worth $55,863,000 after purchasing an additional 222,383 shares in the last quarter. Jump Financial LLC increased its stake in IDEAYA Biosciences by 326.4% in the 3rd quarter. Jump Financial LLC now owns 239,240 shares of the company's stock valued at $9,192,000 after buying an additional 183,131 shares during the last quarter. Aberdeen Group plc increased its stake in IDEAYA Biosciences by 5.3% in the 3rd quarter. Aberdeen Group plc now owns 590,777 shares of the company's stock valued at $22,698,000 after buying an additional 29,843 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in IDEAYA Biosciences by 96.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 100,855 shares of the company's stock valued at $3,875,000 after buying an additional 49,596 shares during the last quarter. Institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

(Get Free Report)

IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company's investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in IDEAYA Biosciences Right Now?

Before you consider IDEAYA Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.

While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines